Conferences
WuXi AppTec Science Forums - US
-
September 16 & 18, 2025
-
Joya Kitchen 10275 Science Center Dr, San Diego, CA 92121 & Le Méridien Boston Cambridge 20 Sidney St, Cambridge, MA 02139
WuXi Science Forum is coming to San Diego and Boston! Join us on September 16 and 18 for the full day of cutting-edge presentations, networking, and scientific exchange focused on accelerating drug discovery and development.
Speakers
Lijuan Hou, M.Sc. | Senior Director, WuXi LTD-DMPK, WuXi AppTec
Lijuan Hou currently serves as the Senior Director in the DMPK Study Director team at WuXi AppTec. She works as an operational leader within the team and is also a key account holder. She joined WuXi AppTec in year of 2007, and over her 18-year career in the ADME field, she has accumulated extensive experience in DMPK research of challenging small molecules and various new modalities, including oligonucleotides and antibody-drug conjugates. Lijuan Hou holds a master’s degree in Microbiology and Biochemistry Pharmacy from Nanjing University, China.
Presentation topic title: Resolving DMPK Complexities in Diverse Therapeutic Modalities
Peng Li, Ph.D. | Associate Director I, WuXi LTD-DMPK, WuXi AppTec
Dr. Peng Li received his Bachelor's and master’s degrees in pharmacy from China Pharmaceutical University. After earning his PhD from the University of Tuebingen, where he specialized in lipidomics and metabolomics, he joined WuXi AppTec as a principal investigator in the DMPK Service Department. Currently, he serves as associate director, using his extensive skills to work with exogenous metabolites in biotransformation studies in support of drug discovery and development. He is passionate about solving complex issues using a mass spectrometry approach. Beyond routine small molecules, his work covers different therapeutic modalities, including peptides, PDCs, and ADCs.
Presentation topic title: Navigating New Modalities: Innovative Solutions for TIDES Biotransformation
Agenda
2025 Science Forum —— San Diego
• Date: Tuesday, September 16, 2025
• Time: 9:30-15:00 (PDT)
2025 Science Forum —— Boston
• Date: Thursday, September 18, 2025
• Time: 9:30-15:00 (EDT)
Our posters
Other Resources
-
Our posters -
Other Resources
-
-
Evaluation of Clearance Prediction Methods for Vepdegestrant (ARV-471) Using PBPK Modelling: Insights into PROTAC Clinical Pharmacokinetics
Recently, vepdegestrant (ARV-471), an orally bioavailable Proteolysis-targeting chimaeras (PROTACs, proteolysis-targeting chimaeras) targeting the estrogen receptor (ER, estrogen receptor), was submitted as a New Drug Application (NDA, New Drug Application) to the U.S. Food and Drug Administration (FDA, Food and Drug Administration) for the treatment of ESR1-mutated (Estrogen Receptor 1-mutated), ER+ (Estrogen Receptor-positive), HER2- (Human Epidermal Growth Factor Receptor 2-negative) advanced or metastatic breast cancer. This submission represents a significant milestone, as ARV-471 may become the first FDA-approved PROTAC degrader, highlighting the growing clinical potential of PROTAC technology.
The Determinants in Evaluating siRNA Plasma Protein Binding Using Agarose Gel Electrophoretic Mobility Shift Assay (EMSA)Does the Flux Competition Method Add Significant Value in Species Difference Protein Binding Evaluation?Effects of Lipoprotein Binding and Plasma Dilution on the Accuracy of Ultracentrifugation Method in Plasma Protein BindingPlasma Protein Binding of Oligonucleotides Using Rapid Agarose Gel Electrophoretic Mobility Shift AssayStrategies for Enhancing Oral Exposure of Water-Insoluble CompoundsPlasma Protein Binding of Nine Antisense Oligonucleotides by UltrafiltrationEstablishment of the Flux Dialysis Method for Highly Bound Compounds in Human Plasma and Rat Brain HomogenateDAR Distribution Determination for Antibody-drug-conjugates (ADCs) by LC-HRMS in In Vitro and In Vivo StudiesView More -
-
-
Evaluating Oral Peptides' Gastrointestinal Absorption: Methods and Applications
ArticlesAug 28,2025
-
Advancing Novel Therapeutics with Innovative DMPK Strategies in Metabolism and Bioanalysis
WebinarsAug 22,2025 -
Optimizing Liposomes/LNPs: From Lipid Solvent Screening to Formulation Stability in PK Studies
ArticlesAug 22,2025
-
Related Services and Platforms
-
Novel Drug Modalities DMPK Enabling PlatformsLearn More -
Therapeutic Areas DMPK Enabling PlatformsLearn More
-
PROTAC DMPK ServicesLearn More
-
ADC DMPK ServicesLearn More
-
Oligo DMPK ServicesLearn More
-
PDC DMPK ServicesLearn More
-
Peptide DMPK ServicesLearn More
-
mRNA DMPK ServicesLearn More
-
Covalent Drugs DMPK ServicesLearn More
-
Ophthalmic Drugs DMPK ServicesLearn More
-
CNS Drugs DMPK ServicesLearn More
-
Respiratory Drugs DMPK ServicesLearn More
-
Topical and Transdermal Drugs DMPK ServicesLearn More
Stay Connected
Keep up with the latest news and insights.
